1 February 2018 - - Dublin, Ireland-based global healthcare company Perrigo company plc (NYSE; TASE: PRGO) has received tentative approval from the US Food and Drug Administration for the generic version of Soolantra (ivermectin) cream, 1%, the company said.
Soolantra (ivermectin) cream, 1% is indicated for the treatment of inflammatory lesions of rosacea.
Perrigo executive vice president and president Rx Pharmaceuticals John Wesolowski said, "This is the Rx team's fifth generic product approval this month. This tentative approval further illustrates our commitment to advancing our new product pipeline and providing savings to patients and healthcare systems."
Perrigo manufactures over-the-counter (OTC) healthcare products and supplies infant formulas for the store brand market, as well as producing "extended topical" prescription drugs. The company sells its products primarily in North America and Europe, as well as in Australia, Israel, and China.